Anti CD5 CAR-T cell therapy ( Shanghai Yake Biotechnology)(Anti CD5 CAR-T cell therapy ( Shanghai Yake Biotechnology)) - 药物靶点：CD5_在研适应症：淋巴瘤，前体T淋巴细胞白血病淋巴瘤_专利_临床

概要

基本信息

药物类型

CAR-T

别名-

靶点

CD5

作用机制

T细胞表面糖蛋白CD5抑制剂、T淋巴细胞替代物

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [1]

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

湖南中医药大学第一附属医院Beijing Boren Hospital

最高研发阶段早期临床1期

首次获批日期-

最高研发阶段(中国)早期临床1期

特殊审评-

登录后查看时间轴

关联

2

项与 Anti CD5 CAR-T cell therapy ( Shanghai Yake Biotechnology) 相关的临床试验

NCT06633341 / Recruiting早期临床1期IIT

A Clinical Study on the Safety and Effectiveness of Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

A Clinical Study on the Safety and Effectiveness of targeting CD5 CAR-T Cells in the treatment of r/r CD5+ T-lymphoma

开始日期2024-10-20

申办/合作机构

浙江大学

[+1]

NCT06633354 / Recruiting早期临床1期IIT

A Clinical Study on the Safety and Effectiveness of Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL

A Clinical Study on the Safety and Effectiveness of targeting CD5 CAR-T Cells in the treatment of r/r CD5+ T-ALL

开始日期2024-10-20

申办/合作机构

浙江大学

[+1]

100 项与 Anti CD5 CAR-T cell therapy ( Shanghai Yake Biotechnology) 相关的临床结果

登录后查看更多信息

100 项与 Anti CD5 CAR-T cell therapy ( Shanghai Yake Biotechnology) 相关的转化医学

登录后查看更多信息

100 项与 Anti CD5 CAR-T cell therapy ( Shanghai Yake Biotechnology) 相关的专利（医药）

登录后查看更多信息

2

项与 Anti CD5 CAR-T cell therapy ( Shanghai Yake Biotechnology) 相关的文献（医药）

2021-04-01·Stem Cell Reviews and Reports3区 · 医学

Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells

3区 · 医学

Article

作者: Sun, Lihua ; Shan, Huiming ; Jiang, Xun ; Feng, Jia ; Wang, Xingen ; Hanes, William M ; Zhang, Wenli ; Zhang, Ping ; Zhang, Qian ; Wada, Masayuki ; Chen, Qi ; Wu, Zehua ; Pinz, Kevin G ; Cinquina, Andrew ; Zhang, Hongyu ; Xu, Haichan ; Ma, Yupo ; Xu, Lei

AbstractWhile treatment for B-cell malignancies has been revolutionized through the advent of CAR immunotherapy, similar strategies for T-cell malignancies have been limited. Additionally, T-cell leukemias and lymphomas can commonly metastasize to the CNS, where outcomes are poor and treatment options are associated with severe side effects. Consequently, the development of safer and more effective alternatives for targeting malignant T cells that have invaded the CNS remains clinically important. CD5 CAR has previously been shown to effectively target various T-cell cancers in preclinical studies. As IL-15 strengthens the anti-tumor response, we have modified CD5 CAR to secrete an IL-15/IL-15sushi complex. In a Phase I clinical trial, these CD5-IL15/IL15sushi CAR T cells were tested for safety and efficacy in a patient with refractory T-LBL with CNS infiltration. CD5-IL15/IL15sushi CAR T cells were able to rapidly ablate the CNS lymphoblasts within a few weeks, resulting in the remission of the patient’s lymphoma. Despite the presence of CD5 on normal T cells, the patient only experienced a brief, transient T-cell aplasia. These results suggest that CD5-IL15/IL15sushi CAR T cells may be a safe and useful treatment of T-cell malignancies and may be particularly beneficial for patients with CNS involvement.Graphical Abstract

Frontiers in Immunology

Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma

Article

作者: Han, Yunfeng ; Xiao, Min ; Huang, Liang ; Shen, Kefeng ; Mao, Xia ; Hu, Guang ; Dai, Zhenyu ; Zhou, Xiaoxi ; Mu, Wei ; Ao, Qilin ; Zhu, Xiaojian ; Chen, Caixia ; Zhang, Meilan

BackgroundAnaplastic Large Cell Lymphoma (ALCL) is one of the most common subtypes of T-cell lymphoma. Among these, refractory and relapsed (r/r) ALK positive ALCL lacks effective therapies. The chimeric antigen receptor-modified T (CAR-T) cell therapy holds great promise as a therapeutic strategy for this disease. However, it is not known yet whether anti-CD5 CAR-T cells are sufficient for the definitive treatment of relapsed ALK+ ALCL, nor the role of accurate laboratory-based diagnoses during CAR-T treatment.Case presentationThe adolescent patient received autologous T cells containing sequences encoding VH domains specific to CD5. Following the infusion, there was an increase in both the copy number and proportion of CAR-T cells in peripheral blood. IL-6 and ferritin levels in the patient exhibited significant fluctuations, with increases of 13 and 70 folds respectively, compared to baseline after the treatment. Additionally, adverse effects were observed, including grade 4 rash, grade 1 headache, nausea, and neck-pain. Surprisingly, a relapsed disease phenotype was identified based on the results of PET/CT and histopathological analysis of the inguinal lymph node biopsy. After conducting a thorough diagnostic assessment, which included flow cytometry, next-generation sequencing (NGS), examination of immune-related gene rearrangements, and analysis of the immune repertoire of T-cell receptors (TCR), we conclusively determined that the hyperplastic T cells identified in the lymph node were the result of an expansion of CAR-T cells. Ultimately, the patient has attained complete remission (CR) and has sustained a disease-free survival state for 815 days as of the cutoff date on August 30, 2023.ConclusionTaken together, the results demonstrate that anti-CD5 CAR-T cells can induce a clinical response in r/r ALK+ ALCL patient. Furthermore, this case underscores the importance of utilizing advanced technologies with high sensitivity and accuracy for biological detection in clinical laboratory diagnosis and prognosis in CAR-T cell treatment.Trial registration numberNCT04767308.

100 项与 Anti CD5 CAR-T cell therapy ( Shanghai Yake Biotechnology) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
淋巴瘤	临床1期	中国	浙江大学	2024-10-20
淋巴瘤	临床1期	中国	上海雅科生物科技有限公司	2024-10-20
前体T淋巴细胞白血病淋巴瘤	临床1期	中国	浙江大学	2024-10-20
前体T淋巴细胞白血病淋巴瘤	临床1期	中国	上海雅科生物科技有限公司	2024-10-20
血液肿瘤	临床1期	中国	上海雅科生物科技有限公司	-
血液肿瘤	临床1期	中国	湖南中医药大学第一附属医院	-
前体B细胞成淋巴细胞白血病淋巴瘤	临床1期	中国	上海雅科生物科技有限公司	-
前体B细胞成淋巴细胞白血病淋巴瘤	临床1期	中国	Beijing Boren Hospital	-